FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017079422> ?p ?o ?g. }

• W2017079422 endingPage "325" @default.
• W2017079422 startingPage "319" @default.
• W2017079422 abstract "Two different enzyme preparations are used for the treatment of Fabry disease patients, agalsidase alpha (Replagal, Shire) and agalsidase beta (Fabrazyme, Genzyme). Therapeutic efficacy of both products has been variable probably due to differences in gender, severity, age and other patient characteristics. We studied the occurrence of alpha-Gal A antibodies and their effect on urinary and plasma globotriaosylceramide (GL-3), plasma chitotriosidase and clinical outcome in 52 patients after 12 months of treatment with either 0.2mg/kg agalsidase alppha (10 males, 8 females) or beta (8 males, 5 females) or 1.0mg/kg agalsidase beta (10 males, 11 females). Antibodies were detected in 18/28 male patients after 6 months. None of the females developed antibodies. Following 12 months of 0.2mg/kg treatment, urinary GL-3 decreased in antibody negative (AB-) but increased in antibody positive (AB+) patients. Treatment with 1.0mg/kg gave a reduction in urinary GL-3 in both AB- and AB+ patients. Levels of plasma GL-3 and chitotriosidase decreased in all patient groups. Twelve months of 0.2mg/kg treatment did not change renal function or left ventricular mass. Further, no change in renal function was seen following 1.0mg/kg treatment and left ventricular mass decreased in both AB- and AB+ patients. In summary, alpha-Gal A antibodies frequently develop in male Fabry disease patients and interfere with urinary GL-3 excretion. Infusion of a dose of 1.0mg/kg results in a more robust decline in GL-3, less impact, if any of antibodies, stable renal function and reduction of LVMass." @default.
• W2017079422 created "2016-06-24" @default.
• W2017079422 creator A5005484331 @default.
• W2017079422 creator A5008321998 @default.
• W2017079422 creator A5013935159 @default.
• W2017079422 creator A5017284273 @default.
• W2017079422 creator A5024669037 @default.
• W2017079422 creator A5029347219 @default.
• W2017079422 creator A5032149781 @default.
• W2017079422 creator A5033368647 @default.
• W2017079422 creator A5045744302 @default.
• W2017079422 creator A5057270664 @default.
• W2017079422 creator A5090883710 @default.
• W2017079422 date "2008-07-01" @default.
• W2017079422 modified "2023-10-18" @default.
• W2017079422 title "Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3" @default.
• W2017079422 cites W1940063962 @default.
• W2017079422 cites W1999636421 @default.
• W2017079422 cites W1999926126 @default.
• W2017079422 cites W2000846576 @default.
• W2017079422 cites W2017870703 @default.
• W2017079422 cites W2024304683 @default.
• W2017079422 cites W2026923881 @default.
• W2017079422 cites W2040721946 @default.
• W2017079422 cites W2041953538 @default.
• W2017079422 cites W2046037112 @default.
• W2017079422 cites W2052295435 @default.
• W2017079422 cites W2054960780 @default.
• W2017079422 cites W2058211622 @default.
• W2017079422 cites W2069816309 @default.
• W2017079422 cites W2071598008 @default.
• W2017079422 cites W2078154626 @default.
• W2017079422 cites W2098886231 @default.
• W2017079422 cites W2099728000 @default.
• W2017079422 cites W2103540959 @default.
• W2017079422 cites W2120445861 @default.
• W2017079422 cites W2125879510 @default.
• W2017079422 cites W2136689144 @default.
• W2017079422 cites W2137603650 @default.
• W2017079422 cites W2149357832 @default.
• W2017079422 cites W2160213856 @default.
• W2017079422 cites W2166434234 @default.
• W2017079422 cites W2166716213 @default.
• W2017079422 cites W2313827278 @default.
• W2017079422 cites W2730938425 @default.
• W2017079422 cites W4252272124 @default.
• W2017079422 doi "https://doi.org/10.1016/j.ymgme.2008.03.003" @default.
• W2017079422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18424138" @default.
• W2017079422 hasPublicationYear "2008" @default.
• W2017079422 type Work @default.
• W2017079422 sameAs 2017079422 @default.
• W2017079422 citedByCount "119" @default.
• W2017079422 countsByYear W20170794222012 @default.
• W2017079422 countsByYear W20170794222013 @default.
• W2017079422 countsByYear W20170794222014 @default.
• W2017079422 countsByYear W20170794222015 @default.
• W2017079422 countsByYear W20170794222017 @default.
• W2017079422 countsByYear W20170794222018 @default.
• W2017079422 countsByYear W20170794222019 @default.
• W2017079422 countsByYear W20170794222020 @default.
• W2017079422 countsByYear W20170794222021 @default.
• W2017079422 countsByYear W20170794222022 @default.
• W2017079422 countsByYear W20170794222023 @default.
• W2017079422 crossrefType "journal-article" @default.
• W2017079422 hasAuthorship W2017079422A5005484331 @default.
• W2017079422 hasAuthorship W2017079422A5008321998 @default.
• W2017079422 hasAuthorship W2017079422A5013935159 @default.
• W2017079422 hasAuthorship W2017079422A5017284273 @default.
• W2017079422 hasAuthorship W2017079422A5024669037 @default.
• W2017079422 hasAuthorship W2017079422A5029347219 @default.
• W2017079422 hasAuthorship W2017079422A5032149781 @default.
• W2017079422 hasAuthorship W2017079422A5033368647 @default.
• W2017079422 hasAuthorship W2017079422A5045744302 @default.
• W2017079422 hasAuthorship W2017079422A5057270664 @default.
• W2017079422 hasAuthorship W2017079422A5090883710 @default.
• W2017079422 hasConcept C126322002 @default.
• W2017079422 hasConcept C126894567 @default.
• W2017079422 hasConcept C134018914 @default.
• W2017079422 hasConcept C159641895 @default.
• W2017079422 hasConcept C159654299 @default.
• W2017079422 hasConcept C203014093 @default.
• W2017079422 hasConcept C2776788019 @default.
• W2017079422 hasConcept C2777288759 @default.
• W2017079422 hasConcept C2777404818 @default.
• W2017079422 hasConcept C2777687718 @default.
• W2017079422 hasConcept C2779134260 @default.
• W2017079422 hasConcept C71924100 @default.
• W2017079422 hasConcept C77411442 @default.
• W2017079422 hasConcept C90924648 @default.
• W2017079422 hasConceptScore W2017079422C126322002 @default.
• W2017079422 hasConceptScore W2017079422C126894567 @default.
• W2017079422 hasConceptScore W2017079422C134018914 @default.
• W2017079422 hasConceptScore W2017079422C159641895 @default.
• W2017079422 hasConceptScore W2017079422C159654299 @default.
• W2017079422 hasConceptScore W2017079422C203014093 @default.
• W2017079422 hasConceptScore W2017079422C2776788019 @default.
• W2017079422 hasConceptScore W2017079422C2777288759 @default.
• W2017079422 hasConceptScore W2017079422C2777404818 @default.

• next